SomaLogic named “Company of the Year” at Colorado BioScience Association’s 2015 Awards Dinner

SomaLogic named “Company of the Year” at Colorado BioScience Association’s 2015 Awards Dinner

11/12/2015

SomaLogic was recognized as “Company of the Year” by the Colorado BioScience Association (CBSA) at its 12th Annual Awards Dinner in Denver, CO, on November 12, 2015. SomaLogic was cited for developing “a new proteomics technology with a mission to leverage its proprietary technology to discover, develop and commercialize revolutionary new life science research tools and breakthrough clinical diagnostic products that will transform healthcare.” Chairman and Founder Larry Gold and CEO Byron Hewett accepted the award on behalf of the company.

CBSA represents more than 350 member organizations, including biotechnology, pharmaceutical, medical device, diagnostic, ag bio and mobile digital health companies, research and academic institutions and service providers.
For more information, please visit the CBSA website.


SomaLogic launches new, larger commercial version of SOMAscan assay

SomaLogic launches new, larger commercial version of SOMAscan assay

9/23/2015

SomaLogic announced today that the latest version of its proprietary SOMAscan proteomics assay, which now measures 1,310 protein analytes, is commercially available to the life science research community. Called “SOMAscan Assay 1.3k,” this new version is replacing the current 1,129-measurement version, but without an increase in price.

“We are committed to increasing our already substantial lead in providing sensitive, accurate and highly multiplexed proteomics tools for novel biomarker discovery and development,” said Byron Hewett, Chief Executive Officer. “We plan to continue growing the number and diversity of proteins measured in our commercially available SOMAscan assay on a regular basis.”

Compared to other current proteomic technologies, SomaLogic’s SOMAscan assay offers its research users unprecedented power for novel protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer reagents, which are at the center of SomaLogic’s proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. SOMAscan Assay 1.3k, which incorporates 1,310 different SOMAmer reagents, can efficiently, accurately, and rapidly measure proteins from high to very low concentrations in small volumes of many different biological sample types.

Many of the nearly 200 new SOMAmer reagents added to the SOMAscan menu target proteins in inflammatory and oncology-related molecular pathways, a particular focus requested by current users of the assay. A list of the 1,310 proteins measured in SOMAscan Assay 1.3k may be downloaded from the SomaLogic website.

SOMAscan Assay 1.3k is primarily available as a service directly from SomaLogic, but access to the assay is also available at a growing number of select biomedical research centers. During the transition to the new SOMAscan version, the 1,129-analyte assay will remain available for a short time at a reduced rate.


SomaLogic announces deployment of SOMAscan™ assay to University of Houston and Sidra Medical and Research Center

SomaLogic announces deployment of SOMAscan™ assay to University of Houston and Sidra Medical and Research Center

9/9/2015

SomaLogic announced today that the University of Houston (Houston, TX) and Sidra Medical and Research Center (Doha, Qatar) are the latest academic centers to deploy SomaLogic’s proprietary SOMAscan assay to accelerate protein biomarker discovery and development across multiple life science research studies in their respective institutions.

Ena Wang, MD, Division Chief of Translational Medicine and Jean-Charles Gravel, PhD, Director of Deep Phenotyping Core facility will oversee the SOMAscan deployment at Sidra Medical and Research Center; and Chandra Mohan, MD, PhD, the Hugh Roy and Lillie Cranz Cullen Endowed Professor in Biomedical Engineering is directing the deployment at the University of Houston.

Compared to other current proteomic technologies, SomaLogic provides researchers with unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer® (Slow Off-rate Modified Aptamer) reagents, which are at the center of SomaLogic’s proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates over 1,000 different SOMAmer reagents, can efficiently, accurately, and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types.

“We are delighted that the University of Houston and Sidra Medical Research Center, under the capable leadership of Drs. Mohan, Wang and Gravel respectively, have joined a growing number of high quality biomedical research centers and scientists using our SOMAscan assay,” said Byron Hewett, Chief Executive Officer of SomaLogic. “We believe that the continued expansion of access to our technology will help accelerate critical new discoveries in biology and medicine.”

Other sites where the SOMAscan assay has been deployed include Massachusetts General Hospital, the University of Pennsylvania, the US National Institutes of Health, the University of Colorado Denver, the University of Manitoba’s Centre for Proteomics and Systems Biology, and the Weill Cornell Medical College in Qatar. Additional SOMAscan assay sites will be announced in the next several months.


SomaLogic and Otsuka Pharmaceutical extend research collaboration for therapeutic SOMAmer development

SomaLogic and Otsuka Pharmaceutical extend research collaboration for therapeutic SOMAmer development

8/10/2015

SomaLogic, Inc. announced today that Otsuka Pharmaceutical Co., Ltd. has extended its initial collaboration agreement with SomaLogic to continue the development of several SOMAmer® therapeutics. Specific projects and financial terms in the extended agreement were not disclosed.

“SOMAmer molecules are a promising new class of drug entities, and we are excited to continue our work with SomaLogic to fully realize that promise,” said Takayuki Shiratsuchi, Operating Officer and General Manager of Basic Research at Otsuka Pharmaceutical. “We are optimistic that extending this collaboration will help accelerate several of our ongoing therapeutics discovery and development efforts.”
SomaLogic is the recognized leader in the development and application of advanced aptamer technologies. The company has designed its proprietary SOMAmer (Slow Off-rate Modified Aptamer) reagents to combine the wide target range of antibodies with the consistency and reproducibility of traditional aptamers. The chemical addition of “protein-like” side chains to the nucleic acid bases that comprise a SOMAmer molecule results in the ability to discover molecules that bind specifically and tightly to virtually any targeted protein. These properties allow SOMAmer molecules to be used in virtually any laboratory or clinical application that currently uses monoclonal antibodies, including therapeutics. For example, SOMAmer molecules have been demonstrated to be potent inhibitors of specific targeted proteins. This property, along with other unique characteristics, makes SOMAmer candidates attractive for novel therapeutic discovery and development.

“We are delighted that our Otsuka colleagues see the value of our technology, and have chosen to extend their productive collaboration with us,” said Byron Hewett, CEO of SomaLogic. “The projects we are continuing to develop with them hold great potential for bringing novel therapeutics to the clinic for several unmet clinical needs.”


SomaLogic announces commercial availability of individual SOMAmer reagents

SomaLogic announces commercial availability of individual SOMAmer reagents

7/8/2015

SomaLogic, Inc. announced today that it is making its proprietary SOMAmer (Slow Off-rate Modified Aptamers) reagents commercially available as individual molecules to the life science and biopharma scientific communities for their specific protein-affinity research needs. The initial library available today includes 244 different SOMAmer reagents (and protein targets), and that number is expected to grow over the coming months.

SOMAmer reagents combine the wide target range and high specificity of antibodies with the durability and consistency of aptamers, thus overcoming the well-known limitations of both these traditional affinity reagents. This combination of attributes is a result of the unique “protein-like” modifications made to the DNA bases that comprise the SOMAmer reagent, and the amenability of those modifications to established DNA synthesis and detection techniques.

“We recognize that there is a significant need for robust and reliable protein-affinity reagents in the wider research community, as evidenced by recent commentaries on the problems of reproducibility, reliability and consistency of commercially available antibodies,” said Paul Menter, VP and General Manager, Life Sciences. “We believe that researchers will find that our SOMAmer reagents are superior performers in virtually every protein detection and measurement application that currently uses antibodies or traditional aptamers.”

To date, SOMAmer reagents have been used successfully by SomaLogic researchers and their collaborators in multiple protein-related laboratory methods, including:

  • Tissue histochemistry
  • Fluorescence-activated cell sorting (FACS)
  • Affinity purification
  • Enrichment or depletion prior to mass spectrometry
  • Sandwich assays
  • Antagonism of protein activity

Detailed Application Notes describing each of these uses are available on the SomaLogic website.

The initial catalog being made commercially available today consists of 244 different SOMAmer reagents that carry a 5′ biotin label. SomaLogic will add new SOMAmer reagents against additional proteins, as well as reagents with different 5′ modifications, on a regular basis. However, researchers can also take advantage of SomaLogic’s SOMAmer Discovery Service to have a superior protein-binding reagent tailor-made to their specific requirements.

SomaLogic is making its SOMAmer reagents available on a Research Use Only basis.


Weill Cornell Medical College in Qatar and SomaLogic announce agreement to deploy the automated version of SOMAscan assay

Weill Cornell Medical College in Qatar and SomaLogic announce agreement to deploy the automated version of SOMAscan assay

6/15/2015

Weill Cornell Medical College in Qatar (WCMC-Q) and SomaLogic announced today that the automated version of the SOMAscan assay, which has been previously available only at SomaLogic’s headquarters in Boulder, CO, will be installed at the WCMC-Q Education City campus in Doha, Qatar. In addition to being the first automated site outside of SomaLogic, this is also the first placement of the SOMAscan assay outside of North America.

“The SOMAscan assay is a key component of the cutting edge biomedical technology provided in Qatar by Weill Cornell Medical College,” said Johannes Graumann, Ph.D., Assistant Professor of Biochemistry and Director of the Proteomics Core at Weill Cornell Medical College in Qatar. “It will help us achieve our mission to support and foster cross-institutional collaboration, improve our understanding of disease mechanisms, identify markers of disease and progression, and to ultimately improve patient care.”

Shahrad Taheri, MBBS, PhD, Professor of Medicine and Director of the Clinical Research Core at WCMC-Q, said: “SomaLogic’s technology can potentially allow more personalized assessment of disease risk and, therefore, better preventive measures. Furthermore, once disease occurs it may be possible to reverse or delay it through greater understanding of treatment selection and responses to treatment measures. This will provide a revolutionary advance to modern medical care.”

Compared to other current proteomic technologies, SomaLogic provides researchers with unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer® (Slow Off-rate Modified Aptamer) reagents, which are at the center of SomaLogic’s proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates 1129 different SOMAmer reagents, can efficiently, accurately, and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types. The automated version of the SOMAscan assay being installed at WCMC-Q can be configured to analyze 100 or more biological samples a day.

“We are delighted that Weill Cornell Medical College is providing the SOMAscan assay to its researchers by making it available at their state-of-the-art Qatar location, and under the leadership of such capable scientists” said Byron Hewett, Chief Executive Officer of SomaLogic. “We anticipate many significant new insights into disease diagnosis and treatment to come from their work.”
SomaLogic is continuing to expand access to its SOMAscan assay through its placement in leading academic research centers. Current sites, in addition to WCMC-Q, include Massachusetts General Hospital, the University of Pennsylvania, the US National Institutes of Health, the University of Colorado Denver, and the University of Manitoba’s Centre for Proteomics and Systems Biology. Additional SOMAscan assay sites – both the automated and manual versions – will be announced in the next several months.